-
1 week ago | 
ark-invest.com | Nemo focuses |Daniel C. Maguire |Sam Korus |Brett Winton
Last week, Elon Musk’s xAI named Polymarket X’s official prediction-market partner. Living inside Polymarket’s interface, Grok already is providing conversational summaries (“Ask Grok”) on every market page.
-
1 month ago | 
ark-invest.com | Nemo focuses |Nemo Marjanovic |Brett Winton
In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics.
-
1 month ago | 
ark-invest.com | Nemo focuses |Nemo Marjanovic |Brett Winton
In this episode of FYI - For Your Innovation, ARK’s Chief Futurist, Brett Winton, and Research Analyst Nemo Marjanovic, sit down with Dr. Jin Hyung Lee, a leading neuroscience researcher at Stanford University. Dr. Lee and her team are pioneering breakthroughs in understanding brain function—an essential step toward diagnosing and treating neurological disorders.
-
Mar 16, 2025 | 
ark-invest.com | Nemo focuses |Brett Winton |Nemo Marjanovic |Tasha Keeney
Apple has delayed the release of some of its most widely touted Apple Intelligence features until 2026 or later.1 Though the delay may be a surprise to seasoned Apple observers,2 disruptive technologies are challenging for incumbents—now including Apple—to incorporate.3 The characteristics that make AI interesting may not be consistent with Apple’s buttoned-up, optimized ecosystem.
-
Jan 24, 2025 | 
ark-invest.com | Nemo focuses |Nemo Marjanovic |Brett Winton
In this episode of FYI, Brett Winton and Nemo Marjanovic sit down with Professor Thomas Hartung, MD-PhD, a leading expert in biomedical innovation at Johns Hopkins Bloomberg School of Public Health. They explore how human organoids—3D organ proxies—are revolutionizing drug discovery and toxicology testing by reducing reliance on animal models.
-
Jan 21, 2025 | 
ark-invest.com | Nemo focuses |Daniel C. Maguire |Brett Winton |Nemo Marjanovic
Biotech investors are witnessing a growing divergence between private and public markets, both in valuations and performance. Private investors are betting on long-term innovation, while public markets are focusing on short-term profitability. Will regulatory and economic shifts close that gap? In 2024, the private market in biotech bounced back with 96 megarounds (nine-figure financing) that approached the 106 funded in 2021.
-
Oct 28, 2024 | 
ark-invest.com | Nemo focuses |Tasha Keeney |Sam Korus |Daniel C. Maguire
What if every baby were to be assessed at birth by whole genome sequencing (WGS) to identify health issues, including hundreds of potential genetic disorders? New studies like the NHS Generation7 Study in the UK and GUARDIAN8 in the US are providing a glimpse into how WGS will shift healthcare from reactive care of the sick to a proactive, precision-based solution. How close are we to realizing that future, and what would it mean?
-
Sep 9, 2024 | 
ark-invest.com | Nemo focuses |Lorenzo focuses |Nemo Marjanovic |Tasha Keeney
Last week, Google’s DeepMind released AlphaProteo, a cutting-edge AI system that designs proteins which bind tightly to target molecules and could accelerate research in the development of drugs, diagnostics, and more. Proteins interact to regulate cellular processes.
-
Aug 26, 2024 | 
ark-invest.com | Nemo focuses |Tasha Keeney |Daniel C. Maguire |Nemo Marjanovic
We’re excited to see Baidu and Waymo scaling their robotaxi operations. Last week, Waymo confirmed that its sixth-generation robotaxi, developed by Geely’s Zeekr, will cut the number of onboard cameras from 29 to 13 and lidar sensors from five to four, compared to the hardware on Waymo’s Jaguar I-PACE.1 Although Waymo has not disclosed details, the cost of the new vehicle is likely to be much lower than the rumored ~$100,000+ for the current model2 —a critical step toward scaling operations.
-
Aug 19, 2024 | 
ark-invest.com | Nemo focuses |Lorenzo focuses |Nemo Marjanovic |Lorenzo Valente
Sakana AI, a Tokyo-based AI research lab founded by former Google employees, recently released details on a new project called “The AI Scientist.” This “agentic”6 system is designed to automate the entire scientific process by combining the powerful capabilities of large language models, including language comprehension, planning, reasoning, and coding skills. AI Scientist follows the process illustrated below. Source: Sakana AI. For illustrative purposes only.
